Abstract: [PROBLEMS TO BE SOLVED] To provide a method of advantageously improving a transdermal permeation amount of a steroid drug to diseased portions when treating ophthalmic diseases such as chalazion, blepharitis, allergic conjunctivitis, vernal keratoconjunctivitis, and meibomian gland dysfunction. [SOLUTION] To provide the transdermal drug delivery system for administering a drug via the eyelid skins that have been treated with a microneedle array, featured in that the drug is a water-soluble steroid, and the transdermal drug delivery system is a water-containing base adhesive skin patch.
Abstract: A patch for treatment of eyelid diseases that is provided with a support, a pressure-sensitive adhesive layer, and a release layer in this order, wherein (a) the pressure-sensitive adhesive layer includes the following (a-1) to (a-4): (a-1) a styrene-isoprene-styrene block copolymer, a tackifier resin, and a softening agent are contained; (a-2) a ratio (mass ratio) of the styrene-isoprene-styrene block copolymer and the tackifier resin is 1:2 to 1:4; (a-3) a content of the softening agent is 40% to 60% by mass; and (a-4) further 0.005% to 5% by mass of clobetasol or acid ester thereof is contained; and (b) the support has elastic modulus with a Young's modulus of 0.01 to 0.5 GPa: and a method for producing the patch for treatment of eyelid diseases including: forming a pressure-sensitive adhesive layer on a upper surface of a release layer.
Abstract: A transdermal drug delivery system comprising a steroid as an active agent, wherein the steroid may be clobetasol propionate, betamethasone dipropionate, amcinonide, or loteprednol etabonate. The transdermal drug delivery system also comprises a pressure-sensitive adhesive layer and a support, wherein the steroid is present in the pressure-sensitive adhesive layer, and wherein the pressure-sensitive adhesive layer is provided on a support. The transdermal drug delivery system may be applied onto the eyelid of a patient in need thereof, in order to treat a disease of the eyelid, such as chalazion, blepharitis or meibomian gland dysfunction.
Abstract: A patch for treatment of eyelid diseases that is provided with a support, a pressure-sensitive adhesive layer, and a release layer in this order, wherein (a) the pressure-sensitive adhesive layer includes the following (a-1) to (a-4): (a-1) a styrene-isoprene-styrene block copolymer, a tackifier resin, and a softening agent are contained; (a-2) a ratio (mass ratio) of the styrene-isoprene-styrene block copolymer and the tackifier resin is 1:2 to 1:4; (a-3) a content of the softening agent is 40% to 60% by mass; and (a-4) further 0.005% to 5% by mass of clobetasol or acid ester thereof is contained; and (b) the support has elastic modulus with a Young's modulus of 0.01 to 0.5 GPa: and a method for producing the patch for treatment of eyelid diseases including: forming a pressure-sensitive adhesive layer on a upper surface of a release layer.
Abstract: The present invention provides an ophthalmic composition comprising a hyperbranched polymer. The ophthalmic compositions may also comprise carbonic anhydrase inhibitors, wherein the hyperbranched polymer increases the aqueous solubility of the carbonic anhydrase inhibitor, and increases corneal permeation of the active agent. The ophthalmic compositions may also comprise non-ionic surfactants, such as polysorbate, hydroxypropyl methyl cellulose or hydroxyethyl cellulose, and beta-blockers, such as carteolol, levobunolol, betaxolol, metipranolol, timolol or propranolol.